| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Lodewijk, Iris |
| dc.contributor.author | Bernardini, Alejandra |
| dc.contributor.author | Suárez-Cabrera, C. |
| dc.contributor.author | Bernal, E. |
| dc.contributor.author | Sánchez-Bayona, Rodrigo |
| dc.contributor.author | Garcia, J. L. |
| dc.contributor.author | Rojas Laimito, Katerin Ingrid |
| dc.date.accessioned | 2022-10-18T12:19:03Z |
| dc.date.available | 2022-10-18T12:19:03Z |
| dc.date.issued | 2022-01-27 |
| dc.identifier.citation | Lodewijk I, Bernardini A, Suárez-Cabrera C, Bernal E, Sánchez R, Garcia JL, et al. Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy. npj Precis Oncol. 2022 Jan 27;6:7. |
| dc.identifier.issn | 2397-768X |
| dc.identifier.uri | https://hdl.handle.net/11351/8311 |
| dc.description | Càncer d'ovari |
| dc.description.sponsorship | This study was funded by GlaxoSmithKline (GSK). I.L. position is funded by Fundación Científica Asociación Española Contra el Cáncer (AECC), Predoctoral AECC 2019 grant number PRDMA19024LODE. L. Morales position is funded by AECC, Postdoctoral AECC 2019 grant number POSTD19036MORA. This study was partially co-funded by European Regional Development Fund (FEDER) grants from Science and Innovation (SAF2015-66015-R and PID2019-110758RB-I00 to J.M.P.) and Instituto de Salud Carlos III (CIBERONC no. CB16/12/00228 to J.M.P.). |
| dc.language.iso | eng |
| dc.publisher | Nature Portfolio |
| dc.relation.ispartofseries | npj Precision Oncology;6 |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Ovaris - Càncer - Tractament |
| dc.subject | Expressió gènica |
| dc.subject | Quimioteràpia combinada |
| dc.subject.mesh | Ovarian Neoplasms |
| dc.subject.mesh | /drug therapy |
| dc.subject.mesh | Gene Expression |
| dc.subject.mesh | Neoadjuvant Therapy |
| dc.title | Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1038/s41698-021-00247-3 |
| dc.subject.decs | neoplasias ováricas |
| dc.subject.decs | /farmacoterapia |
| dc.subject.decs | expresión génica |
| dc.subject.decs | tratamiento neoadyuvante |
| dc.relation.publishversion | https://doi.org/10.1038/s41698-021-00247-3 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Lodewijk I] Biomedical Research Institute I+12, University Hospital “12 de Octubre”, Madrid, Spain. Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain. [Bernardini A] Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain. [Suárez-Cabrera C] Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain. [Bernal E] Medical Oncology, University Hospital 12 De Octubre, Madrid, Spain. Medical Oncology, Infant Cristina University Hospital, Madrid, Spain. [Sánchez R] Medical Oncology, University Hospital 12 De Octubre, Madrid, Spain. [Garcia JL] Pathology Department, University Hospital 12 De Octubre, Madrid, Spain. [Rojas K] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
| dc.identifier.pmid | 35087175 |
| dc.identifier.wos | 000749220900001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |